Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Scancell Holdings plc
  6. News
  7. Press Releases
    SCLP   GB00B63D3314

SCANCELL HOLDINGS PLC

(SCLP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société SCANCELL HOLDINGS PLC
06/22SCANCELL : COVIDITY programme to start Phase I in H221
PU
01/29SCANCELL : H121 results highlight shift to delivery and execution January 2021
PU
01/29SCANCELL : Interim Report 31st October 2020
PU
2020SCANCELL : Redmile funding releases the brakes
PU
2020SCANCELL : Notice of Annual General Meeting November 2020
PU
2020SCANCELL : Annual Report 30th April 2020
PU
2020SCANCELL : Material fund raise means clinical progress in sight
PU
2020SCANCELL : COVID 2nd generation vaccine opportunity is all upside May 2020
PU
2020SCANCELL : Reasons to be cheerful May 2020
PU
2020SCANCELL : to Present at Three Research Conferences
PU
2018SCANCELL : Results of the Placing and Subscription
PU
2018SCANCELL : presents at Calculus Investor Forum
PU
2018SCANCELL : a member of team shortlisted for Cancer Research UK's Grand Challenge Award
PU
2018SCANCELL : Announcement of Share Options 1 February 2018
PU
2018SCANCELL : to collaborate with BioNTech
PU
2017SCANCELL : appoints Dr Cliff Holloway as Chief Executive Officer
PU
2017SCANCELL : Continued progress on SCIB1 – eight patients reach 5 year survival milest..
PU
2017SCANCELL : DNA ImmunoBody® Patent Granted in Europe
PU
2017SCANCELL : Proposed placing to raise up to £5.0 million
PU
2017SCANCELL : to present at the Immuno-Oncology Summit Europe 2017
PU
2017SCANCELL : ALCII - Scancell Collaboration in Lung Cancer
PU
2016SCANCELL : preparing SCIB2 for clinical study in lung cancer
PU
2016SCANCELL : Dr Alan J. Lewis appointed as Non-Executive Director
PU
2016SCANCELL : SCIB1 continues to deliver compelling survival data in melanoma
PU
2016SCANCELL : Opens US Headquarters in San Diego - Key Management Changes to Support Future G..
PU
2016SCANCELL : Collaboration with Karolinska
PU
2016SCANCELL : Firm Placing Raises £3.4 million
PU
2016SCANCELL : Proposed Placing and Open Offer
PU
2016SCANCELL : to present at the Biotech Capital Conference
PU
2016SCANCELL : Directorate Change
PU
2015SCANCELL : AGM Business and R&D Update
PU
2015SCANCELL : strengthens operational and clinical development expertise
PU
2015SCANCELL : and ImmunID announce collaboration to predict SCIB1 responders using ImmunTraCk..
PU
2015SCANCELL : to provide positive SCIB1 Phase 1/2 clinical trial update during corporate pres..
PU
2014SCANCELL : Interim Results for the six months ended 31 October 2014
PU
2014SCANCELL : Appointment of Nominated Adviser and Broker
PU
2014SCANCELL : AGM research and development update highlights progress in both SCIB1 clinical ..
PU
2014SCANCELL : Final Results for the year ended 30 April 2014
PU
2014SCANCELL : DNA ImmunoBody® Patent Granted
PU
2014SCANCELL HOLDINGS PLC : Nottingham Technology Grant
PU
2013SCANCELL HOLDINGS PLC : Grant of Options to Directors
PU
2013SCANCELL HOLDINGS PLC : Unaudited interim results for 6 months ending 31st October 2013
PU
2013SCANCELL HOLDINGS PLC : Holdings in Company
PU
2013SCANCELL HOLDINGS PLC : DNA ImmunoBody® Patent Granted in first market
PU
2013SCANCELL HOLDINGS PLC : Inclusion on the Quotation Board of the Open Market of the Frankfu..
PU
2013SCANCELL HOLDINGS PLC : Holdings in Company
PU
2013SCANCELL HOLDINGS PLC : Result of General Meeting
PU
2013SCANCELL HOLDINGS PLC : Director Shareholdings
PU
2013SCANCELL HOLDINGS PLC : Final Results for the Year End 30 April 2013
PU
2013SCANCELL HOLDINGS PLC : Firm Placing and Open Offer and Notice of General Meeting
PU
2013SCANCELL HOLDINGS PLC : Peter Allen appointed as Non-Executive Director
PU
2012SCANCELL HOLDINGS PLC : Cancer Vaccine Specialist Scancell's SCIB1 Phase 1/2 Clinical Tria..
BU
2012SCANCELL HOLDINGS PLC : Notice of Results and Share Price Movement
PU
2012SCANCELL HOLDINGS PLC : Holdings in Company
PU
2012SCANCELL HOLDINGS PLC : SCIB1 Trial Update
PU
2012SCANCELL HOLDINGS PLC : Holdings in Company
PU
2012SCANCELL HOLDINGS PLC : Investor presentation 2012
PU
2012SCANCELL HOLDINGS PLC : Unaudited Interim Results for the six month period to 31st October..
PU
2010SCANCELL HOLDINGS PLC : (?Scancell Holdings' or the ?Company') Collaboration With ImmuneRe..
BU
2010SCANCELL HOLDINGS PLC : Scancell Signs Antibody Licence Agreement with Cancer Research Tec..
BU
Upcoming event on SCANCELL HOLDINGS PLC
02/01/22